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Identification of a heparin-releasable hepatic lipase binding protein from rat
liver
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Department of Biochemistry, Erasmus University, Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
Hepatic lipase (HL) plays a key role in the metabolism of several
lipoproteins. Metabolically active HL is bound in liver paren-
chymal cells to specific binding sites. We studied the nature of the
HL binding in rat liver. Rat livers were perfused with heparin,
which lead to a loss of 80% of the HL binding capacity of the
liver. The heparin-containing perfusates possessed HL binding
capacity, determined by slot-blot assay. The perfusates were
loaded on to a heparin-Sepharose column and eluted with a
linear salt gradient (0.2–1 M). HL binding activity, assessed by a
slot-blot binding assay, eluted both at 0.3 M and at 0.8 M NaCl.
INTRODUCTION
Hepatic lipase (HL) is found in liver as an extracellularly located
enzyme. The enzyme is synthesized in liver parenchymal cells [1]
and is subsequently bound to the parenchymal cell microvilli [2].
Because of its extracellular localization, HL is able to play an
important role in the metabolism of lipoproteins. A function in
the metabolism of high-density lipoproteins (HDL), inter-
mediate-density lipoproteins (IDL) and chylomicron remnants
[3–9] has been suggested. It has been proposed that, besides its
catalytical activity, HL acts as a ligand for lipoprotein binding to
receptors [10].
Recently, we showed that the binding capacity of the liver for
HL is limited [11], suggesting the presence of (a) specific HL
binding site(s). The specificity of the binding sites was further
substantiated by the finding that, although HL binding capacity
is fully utilized, the structurally related lipoprotein lipase (LPL)
can still be bound to the liver. In addition, LPL was not able to
compete for HL binding in the liver. The nature of the HL
binding site is not known. Heparan sulphate proteoglycans
(HSPGs) may be involved [10,12,13] and the LDL-receptor-
related protein may play a role in the degradation of HL [13].
However, in view of the specificity of HL binding, the HL
binding site should have additional selective properties.
HL is heparin-releasable ; the enzyme is found in the plasma
after heparin injection or in perfusates after heparin-perfusion of
the liver. We found that its binding site is also heparin-sensitive.
Upon perfusion with heparin the HL binding capacity of rat liver
is largely abolished [11]. This indicates either that the HL binding
site is inactivated or that it is, like HL itself, released by heparin.
In the present study we addressed this issue. We showed that
heparin-containing perfusates of rat liver contain HL binding
activity, which is probably exerted by a 73 kDa protein.
MATERIALS AND METHODS
Animals
Male Wistar rats (200–250 g) housed under controlled conditions
Abbreviations used: EDAC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl ; HDL, high-density lipoprotein ; HL, hepatic lipase ; HSPG, heparan
sulphate proteoglycan; IDL, intermediate-density lipoprotein ; LPL, lipoprotein lipase.
1 To whom correspondence should be addressed.
A 0.5 M NaCl eluate was used to further characterize the HL
binding activity. In this fraction the major protein had a
molecular mass of 70 kDa. The fraction showed saturable HL
binding in a solid-phase binding assay. Cross-linking of the
0.5 M NaCl fraction to "#&I-labelled HL yielded a complex of
130 kDa, suggesting the cross-linking of the 57 kDa "#&I-labelled
HL to a protein of about 73 kDa. We concluded that heparin
releases a protein of about 73 kDa from rat liver, which associates
with HL. This protein may represent the HL binding site in liver.
(temperature 20–22 °C, light period from 7.00–19.00 h) with free
access to Purina rat chow and water.
Isolation of HL
HL was isolated from heparin-containing rat liver perfusates as
described previously [14]. HL triacylglycerol hydrolase activity
was measured using an artificial glycerol-[9,10(n-"%C)]-trioleate
(Amersham, Little Chalfont, Bucks., U.K.) emulsion in gum
acacia, pH 8.5 [1]. Purified HL (showing one band on SDS}
PAGE) was labelled with "#&I (Amersham) using lactoperoxidase
and glucose oxidase (both from Boehringer-Mannheim, Mann-
heim, Germany) as described for LPL [15]. After iodination, the
enzyme was separated from free iodine using a heparin-Sepharose
column. The specific activity was in the range of 200–
500 d.p.m.}ng. Iodinated HL was stored at ®80 °C until use.
Heparin-Sepharose chromatography
Heparin-containing perfusates from 2–3 rats (50 ml}rat) were
applied on to a heparin-Sepharose column. After extensive
washing with 10 mM phosphate buffer, pH 7.0, containing 0.2 M
NaCl and 10% (v}v) glycerol, the column was eluted with a
60 ml linear salt gradient (0.2–1.0 M NaCl). Fractions (1 ml)
were collected and tested for HL binding capacity by slot-blot
assay as described below.
In some experiments the column was eluted batch-wise with
10 mM phosphate buffer, pH 7.0, containing 0.5 M NaCl and
subsequently with the same buffer containing 1 M NaCl. The
two fractions were collected, dialysed against 5 mM NH
%
HCO
$
and freeze dried. After resuspension in 0.2–1 ml of PBS the
fractions (which were designated the 0.5 M NaCl fraction and
the 1 M NaCl fraction) were stored at ®80 °C until use.
HL binding assays
Heparin-containing perfusate and fractions (1 ml), eluted with a
linear salt gradient from heparin-Sepharose as described above,
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were spotted on to nitrocellulose and the blot was blocked with
3% (w}v) BSA (Sigma, St. Louis, MO, U.S.A.). Subsequently
the blot was incubated with "#&I-labelled HL (3 lg}ml) in 10 mM
Tris}HCl, pH 8.0, containing 50 mM NaCl, 2 mM CaCl
#
and
1% (w}v) BSA. The blot was washed three times with the same
buffer but without BSA and was scanned using a densitometer
(Scanjet II CX; Hewlett Packard, Meriden, CT, U.S.A.).
For the solid phase binding assay, the wells of enzyme
immunoassay (EIA)}RIA plates (Costar, Cambridge, MA,
U.S.A.) were coated with 10–100 ng of the 0.5 M NaCl fraction
(see the heparin-Sepharose chromatography section), with BSA
(10–100 ng protein) or left uncoated (3 h at room temperature).
After being washed four times with 200 ll of PBS}well, the wells
were blocked overnight at 4 °C with 3% (w}v) BSA in PBS.
Subsequently, the wells were incubated with different amounts of
HL for 2 h at room temperature. The wells were washed four
times with 200 ll PBS}0.1% (v}v) Tween 20 and thereafter
incubated with a mix of monoclonal antibodies against rat HL
[16] (1 :5, 100 ll}well) for 2 h at room temperature. After being
washed four times with 200 ll PBS}0.1% (v}v) Tween 20 per
well, goat anti-mouse IgGs conjugated with alkaline phosphatase
(TAGO Inc., Burlingame, CA, U.S.A. ; 1 :500, 100 ll}well) were
bound for 2 h at room temperature. 4-Nitrophenyl phosphate
(disodium salt) was used as a substrate and the absorbance was
measured at 405 nm using a Thermomax microplate reader
(Sopar Biochem, Nieuwegein, The Netherlands).
Cross-linking experiments
Cross-linking experiments were performed with the 0.5 M NaCl
fraction by incubation with "#&I-labelled HL in the presence of
the covalent linker 1-ethyl-3-(3-dimethylaminopropyl)carbodi-
imide HCl (EDAC; Sigma) as described previously [17]. The
sfraction was incubated with "#&I-labelled HL (3 lg}ml) in the
presence of 11 mM EDAC for 20 min at 4 °C in 20 mM Hepes,
pH 7.4, containing 128 mM NaCl, 5 mM KCl, 5 mM MgCl
#
and
1 mM CaCl
#
. Radioactively labelled proteins were separated by
SDS}PAGE (7.5% gels) followed by autoradiography.
RESULTS
Heparin-releasability of HL binding activity
Upon perfusion with heparin-containing media, over 90% of
HL activity is released into the perfusate. However, although the
liver is depleted of HL, subsequent perfusion with HL-containing
medium does not lead to rebinding of the enzyme. Therefore
heparin either destroys the HL binding site or the binding site is
heparin-releasable. To investigate the latter, heparin-containing
perfusates were tested for HL binding capacity in a slot-blot
assay. The perfusate was transferred on to nitrocellulose paper
and incubated with "#&I-labelled HL. This resulted in a high
binding capacity which was concentration dependent (Figure 1,
bands 1 and 2). To test whether the "#&I-labelled HL binding
represented binding to heparin still present in the perfusate, 10 ll
of 100-fold concentrated heparin perfusate from which heparin
had been removed by ultrafiltration was applied. Binding to
this perfusate was as high as binding to the untreated heparin
perfusate (Figure 1, band 3). Moreover, no binding was observed
when "#&I-labelled HL was incubated with only Berry medium
(140 mM NaCl}5±4 mM KCl}8±18 mM MgSO
%
}0±8 mM
Na
#
HPO
%
}25 mM NaHCO
$
}2±54 mM CaCl
#
}6 mM d-glucose)
containing heparin (Figure 1, band 4). The binding of "#&I-
labelled HL appeared to be specific since the signal on the auto-
radiogram had almost disappeared when the same experiment
Figure 1 HL binding activity in heparin perfusate
Rat liver heparin perfusate was applied on nitrocellulose and incubated with 125I-labelled HL as
described in the Material and Methods section. The left panel shows binding of 125I-labelled
HL : lane 1, perfusate (1 ml) ; lane2, perfusate (0.5 ml) ; lane 3, concentrated perfusate (10 ll)
after removal of heparin ; and lane 4, heparin-containing Berry medium (1 ml), which had not
passed through the liver. The right panel shows the same fractions but after incubation with
125I-labelled HL in the presence of an excess of unlabelled (­cold) HL.
was performed in the presence of an excess of unlabelled HL
(Figure 1, right panel).
Heparin-Sepharose chromatography
Since the heparin-releasability of the HL binding activity suggests
the involvement of heparan sulphates in the binding of the HL
binding site, we investigated whether HL binding activity could
be retained on a heparin-Sepharose column. Therefore heparin-
containing liver perfusates from 2–3 rats were loaded on to a
heparin-Sepharose column and eluted with a linear 0.2–1.0 M
NaCl gradient. Fractions (1 ml) were collected and tested for HL
binding capacity in a slot-blot assay. About 75% of the HL
binding activity was retained on the column and binding activity
was eluted in two major fractions at 0.3 M and 0.8 M NaCl
(Figure 2). The HL binding capacity of the 0.8 M fraction co-
incided with the elution of HL activity (Figure 2).
Further characterization of HL binding in the perfusate was
carried out with fractions obtained after stepwise elution from
Figure 2 HL binding activity in heparin-Sepharose eluate
Heparin-containing rat liver perfusates were loaded on to a heparin-Sepharose column and
eluted with a linear NaCl gradient (0.2–1.0 M). Fractions were collected and tested for HL
binding activity using a slot-blot assay and for HL enzyme activity. About 75% of total binding
activity was retained on the column. Binding activity (E) is expressed as a percentage of the
maximal binding observed and HL enzyme activity (D) is expressed as m-units/ml. The results
are the means of three experiments.
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Figure 3 Proteins present in heparin-Sepharose eluates
Heparin-containing rat liver perfusates were loaded on to a heparin-Sepharose column and were
eluted with 0.5 and 1.0 M NaCl. Fractions were collected and concentrated as described in the
Materials and Methods section. Samples of the fractions (10 ll) were separated by SDS/PAGE
(7.5% gels). Lane 2, whole perfusate before heparin-Sepharose chromatography ; lane 3, 0.5 M
NaCl fraction ; lane 4, 1.0 M NaCl fraction and lane 1, molecular mass markers.
the heparin-Sepharose column with 0.5 M and 1.0 M NaCl
respectively. The protein composition of both fractions was
analysed by SDS}PAGE (Figure 3). The 0.5 M fraction was
found to contain one major protein band of 70 kDa. The 1 M
fraction contained two major protein bands of the same intensity
of respectively 70 kDa and 57 kDa. The 57 kDa band represents
HL, confirmed by Western blotting (results not shown). HL
binding of the 0.5 M fraction was further studied using a solid-
Figure 4 HL binding to the 0.5 M NaCl eluate after heparin-Sepharose
chromatography
The 0.5 M NaCl fraction (see Figure 3, lane 3) was tested for HL binding capacity in a solid
phase binding assay (E). Binding components were coated on to a microtitre plate and
incubated with HL, monoclonal antibodies against HL were then bound followed by incubation
with goat anti-mouse antibodies conjugated with alkaline phosphatase. 4-Nitrophenyl phosphate
(disodium salt) was used as a substrate and the absorbance was measured at 405 nm. As a
control, the wells were coated with BSA and tested for HL binding (^).
Figure 5 Cross-linking of the 0.5 M NaCl fraction with 125I-labelled HL
using EDAC
125I-labelled HL was incubated with a sample of the 0.5 M NaCl eluate from a heparin-
Sepharose column (see Figure 3) and without (lane 1) or with (lane 2) the covalent linker EDAC
for 20 min as described in the Material and Methods section. Incubation of 125I-labelled HL with
(lane 4) or without (lane 3) EDAC in the absence of the 0.5 M NaCl fraction.
phase binding assay. The 0.5 M fraction was coated on to a 96-
well plate and incubated with HL as described in the Materials
and methods section. HL binding to the fraction was saturable ;
saturation was reached at concentrations greater than 10 m-
units}ml, corresponding to 625 ng}ml (Figure 4). As a control,
wells were first coated with BSA and then incubated with HL.
No significant HL binding was found in these wells. These results
indicate that the 0.5 M fraction contains a high-affinity HL
binding factor.
Identification of the HL binding protein
To study the involvement of the 70 kDa protein in HL binding
we performed ligand blotting with the 0.5 M NaCl fraction. The
fraction was subjected to reducing and non-reducing SDS}PAGE
and blotted on to nitrocellulose membranes. The membranes
were incubated with "#&I-labelled HL, and no binding was
observed (results not shown). Since SDS}PAGE may have altered
the HL binding activity, we studied the interaction of HL with
components of the fractions containing HL binding activity by
cross-linking "#&I-labelled HL to the native unmodified fraction.
Upon addition of the cross-linker EDAC to the 0.5 M NaCl
fraction in the presence of "#&I-labelled HL, "#&I-labelled com-
plexes of 130 and 178 kDa were formed (Figure 5, lane 2). The
major labelled band of 57 kDa represents free "#&I-labelled HL.
In the absence of EDAC, only free "#&I-labelled HL was visible
on the autoradiogram (Figure 5, lane 1). When "#&I-labelled HL
was cross-linked with EDAC a 178 kDa complex was formed
(Figure 5, lane 4).
DISCUSSION
HL is specifically bound to rat liver parenchymal cells [2] but
until now no HL binding site has been identified.We have found
that when rat livers are perfused with HL-containing medium no
HL can be bound, indicating that all HL binding sites are
occupied, whereas LPL can still bind to the liver [11]. Fur-
thermore, the largest part of HL activity was bound to a heparin-
sensitive binding site as most binding capacity was lost upon
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heparin perfusion [11]. Moreover, after treatment of rats with
adrenocorticotrophic hormone, HL activity in the liver was de-
creased and the number of heparin-sensitive HL binding sites
had diminished, suggesting that regulation of HL activity in rat
liver may occur at the level of the HL binding sites [11]. In the
present study, we investigated the nature of the heparin-sensitive
binding site. This binding site may be either destroyed or released
by heparin. The latter hypothesis was confirmed by slot-blot
experiments, where heparin-containing perfusates from rat liver
were incubated with "#&I-labelled HL. A high binding capacity
was observed, which was displaced by an excess of unlabelled
HL, indicating that heparin-treated rat liver perfusates contained
specific HL binding components. The high specific binding was
not due to heparin present in the perfusate, because binding to
perfusate from which heparin had been removed by dialysis was
the same as that of untreated heparin perfusate. Moreover,
heparin-containing medium which had not passed through the
liver did not bind HL, providing additional evidence that the
perfusate contains a specific HL binding activity, which cannot
be attributed to the heparin in the medium. Therefore it can be
concluded that the heparin-sensitive binding site of HL is
probably heparin-releasable. However, we were not able to rule
out the possibility that part of the heparin-induced reduction of
HL binding might be due to inactivation of binding sites.
Release of the HL binding site with heparin indicates com-
petition of heparin with HSPGs at the cell surface. There is some
evidence that HSPGs are involved in HL binding [10,12,13].
Heparinase treatment of hepatoma cells overexpressing HL
abolished HL-mediated binding and uptake of chylomicrons and
very-low-density lipoproteins [12]. Also, Kounnas et al. [13]
showed that proteoglycan-deficient Chinese hamster ovary cells
were unable to internalize and degrade HL. However, for HL
binding the HSPG should be specific, as LPL, which is struc-
turally very similar and also binds to HSPGs, was not able to
compete for HL binding. The specificity of HSPGs for the
binding of HL was also suggested by Lookene et al. [18], who did
not find any binding of HL to heparan-sulphate-covered sensor
chips of a BIAcore system, whereas LPL was bound with a high
affinity. It was suggested that this may be due to the source of the
heparan sulphates used (endothelial), as hepatic heparan sul-
phates contain more heparin-like regions [19]. However, it is
tempting to speculate that the lack of binding may have been due
to the absence of a heparin-releasable HL binding component.
Most heparin-releasable proteins bind to heparin-Sepharose,
although with variable affinity. It appeared that HL binding
activity in the heparin perfusates was also retained on a heparin-
Sepharose column. Binding activity eluted in two peaks reaching
a maximum at 0.3 M and 0.8 M NaCl. It is, therefore, possible
that there are two different binding proteins with different
affinities for heparin. However, HL also elutes at an NaCl
concentration of 0.8 M and the peak of HL activity coincided
with the elution of HL binding activity. It seems likely, therefore,
that the second peak represents HL, which eluted together with
its binding site.
When we analysed the proteins in the heparin-Sepharose
eluate, the major protein present in the first peak (0.5 M NaCl
eluate) had an apparent molecular mass of about 70 kDa. In the
1 M NaCl fraction this protein was also one of the major bands
and it was of similar intensity to the 57 kDa band representing
HL. The 70 kDa protein, therefore, appeared to be a good
candidate for the HL binding protein. It is not likely that the
70 kDa protein is albumin, since BSA bound very little HL.
Besides, the 70 kDa band in the total perfusate was clearly
discernable from the albumin band of the marker proteins
and also from the 66 kDa band, which probably represented
rat albumin. Moreover, HL binding was not inhibited by anti-
albumin antibodies (results not shown).
To establish the molecular mass of the HL binding component
we performed ligand blotting experiments. However, after SDS}
PAGE of a heparin-containing liver perfusate, using both re-
ducing and non-reducing conditions, and subsequent blotting,
no HL was bound. Because the presence of SDS could have
changed the conformation of the binding protein to such an
extent that binding of HL was no longer possible, we used
another approach to establish the molecular mass of the binding
protein. Cross-linking experiments were performed with the
0.5 M NaCl eluates, because no endogenous HL was present in
this fraction, and binding of HL to this fraction was found to be
saturable using solid-phase HL binding assays. Incubation of
this fraction, which contained the HL binding component in its
native form, with "#&I-labelled HL in the presence of a cross-
linker resulted in the formation of two complexes, one of 130 kDa
and one of 178 kDa. The latter complex was also formed when
"#&I-labelled HL was cross-linked with EDAC in the absence of
the 0.5 M NaCl eluate, and probably represents a multimer of
HL. This means that HL (which has a molecular mass of 57 kDa)
was crosslinked to a protein of about 73 kDa. Our results show
that a heparin-releasable HL binding protein of about 73 kDa is
present in rat liver. The heparin-releasable HL binding com-
ponent can be bound to heparin. Therefore, in io, this binding
protein probably associates with proteoglycans on the paren-
chymal cell surface. The binding protein itself is not likely to be
a proteoglycan, since these proteoglycans usually smear on
SDS}PAGE. It is also known that proteoglycans do not stain
very well with Coomassie Blue [20], and this was not the case for
the HL binding protein. However, we cannot totally exclude the
possibility that the binding protein is a proteoglycan.
Sivaram et al. [21] found that LPL also associated with a
heparin-releasable binding protein. However, this protein had an
apparent molecular mass of 116 kDa and was found in en-
dothelial cells. As HL is not present in endothelial cells, and as
there is no competition between LPL and HL for binding, this
binding protein is probably not involved in the binding of HL.
We are currently investigating the properties of the heparin-
releasable HL binding protein.
This study was carried out under the auspices of the Netherlands Foundation for
Chemical Research (S.O.N.).
REFERENCES
1 Jansen, H., Kalkman, C., Zonneveld, A. J. and Hu$ lsmann, W. C. (1979) FEBS Lett.
98, 299–302
2 Breedveld, B., Schoonderwoerd, K., Verhoeven, A. J. M., Willemsen, R. and Jansen,
H. (1997) Biochem. J. 321, 425–430
3 Shafi, S., Brady, S. E., Bensadoun, A. and Havel, R. J. (1994) J. Lipid Res. 35,
709–720
4 Homanics, G. E., De Silva, H. V., Osada, J., Zhang, S. H., Wong, H., Borensztajn, J.
and Maeda, N. (1995) J. Biol. Chem. 270, 2974–2980
5 Jansen, H. and Hu$ lsmann, W. C. (1985) Biochem. Soc. Trans. 13, 24–26
6 Marques-Vidal, P., Aze!ma, C., Collet, X., Vieu, C., Chap, H. and Perret, B. (1994)
J. Lipid Res. 35, 373–384
7 Hegele, R. A., Little, J. A., Vezina, C., Maguire, G. F., Tu, L., Wolever, T. S., Jenkins,
D. J. and Connelly, P. W. (1993) Arterioscler. Thromb. 13, 720–728
8 Chang, S. and Borensztajn, J. (1995) Biochim. Biophys. Acta 1256, 81–87
9 Fan, J., Wang, J., Bensadoun, A., Lauer, S. J., Dang, Q., Mahley, R. W. and Taylor,
J. M. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 8724–8728
10 Olivecrona, G. and Olivecrona, T. (1995) Curr. Opin. Lipidol. 6, 291–305
11 Schoonderwoerd, K., Verhoeven, A. J. M. and Jansen, H. (1994) Biochem. J. 302,
717–722
12 Ji, Z. S., Lauer, S. J., Fazio, S., Bensadoun, A., Taylor, J. M. and Mahley, R. W.
(1994) J. Biol. Chem. 269, 13429–13436
13 Kounnas, M. Z., Chappell, D. A., Wong, H., Argraves, W. S. and Strickland, D. K.
(1995) J. Biol. Chem. 270, 9307–9312
789Identification of a hepatic lipase binding protein
14 Jensen, G. L. and Bensadoun, A. (1981) Anal. Biochem. 113, 246–252
15 Saxena, U., Witte, L. D. and Goldberg, I. J. (1989) J. Biol. Chem. 264, 4349–4355
16 Persoon, N. L., Sips, H. J., Hu$ lsmann, W. C. and Jansen, H. (1986) Biochim.
Biophys. Acta 875, 286–292
17 Boensch, C., Kuo, M. D., Connolly, D. T., Huang, S. S. and Huang, J. S. (1995)
J. Biol. Chem. 270, 1807–1816
Received 1 August 1997/20 October 1997 ; accepted 14 November 1997
18 Lookene, A., Savonen, R. and Olivecrona, G. (1997) Biochemistry 36, 5267–5275
19 Lyon, M., Deakin, J. A. and Gallagher, J. T. (1994) J. Biol. Chem. 269,
11208–11215
20 Khan, M. Y. and Newman, S. A. (1991) Anal. Biochem. 196, 373–376
21 Sivaram, P., Klein, M. G. and Goldberg, I. J. (1992) J. Biol. Chem. 267,
16517–16522
